

# diabetes

A JOURNAL OF  
THE AMERICAN  
DIABETES  
ASSOCIATION®

Effect of glyburide in type II diabetes mellitus: studies of monocyte membrane fluidity, lipid composition, and insulin binding N. D. NEUFELD, M. HARRIS, L. M. CORBO, AND A. KODURI	1351
Cytoadherence of lymphocytes from type I diabetic subjects to insulin-secreting cells: marker of anti- $\beta$ -cell cellular immunity F. LANG, D. MAUGENDRE, E. HOUSSAINT, B. CHARBONNEL, AND P. SAI	1356
Insulin secretion and clearance: comparison after oral and intravenous glucose E. T. SHAPIRO, H. TILLIL, M. A. MILLER, B. H. FRANK, J. A. GALLOWAY, A. H. RUBENSTEIN, AND K. S. POLONSKY	1365
Development of rat embryos cultured in glucose-deficient media S. K. L. ELLINGTON	1372
Effect of physical training on insulin action in obesity R. A. DeFRONZO, R. S. SHERWIN, AND N. KRAEMER	1379
Defective vasodilation response to exercise in cutaneous precapillary vessels in diabetic humans M. A. KATZ AND G. McNEILL	1386
Effect of age and sex on rat endocrine pancreas E. P. REAVEN, D. L. CURRY, AND G. M. REAVEN	1397
Tissue culture of human fetal pancreas: effects of human serum on development and endocrine function of isletlike cell clusters S. SANDLER, A. ANDERSSON, A. S. LANDSTRÖM, J. TOLLEMAR, H. BORG, B. PETERSSON, C.-G. GROTH, AND C. HELLERSTRÖM	1401
Impaired cytokine response in male ICR swiss mice after infection with D variant of encephalomyocarditis virus N. J. BIGLEY, R. A. BLAY, AND R. A. SMITH	1408
Na <sup>+</sup> -K <sup>+</sup> -ATPase pumping activity is not directly linked to <i>myo</i> -inositol levels after sorbinil treatment in lenses of diabetic rats L.-A. YEH, C. E. RAFFORD, K. J. GODDU, M. A. ASHTON, T. A. BEYER, AND N. J. HUTSON	1414
Cholecystokinin-induced alterations in $\beta$ -cell sensitivity: duration, specificity, and involvement of phosphoinositide metabolism W. S. ZAWALICH, V. A. DIAZ, AND K. C. ZAWALICH	1420
Does galactose feeding provide a valid model of consequences of exaggerated polyol-pathway flux in peripheral nerve in experimental diabetes? G. B. WILLARS, J. E. LAMBOURNE, AND D. R. TOMLINSON	1425
64,000-M <sub>r</sub> autoantigen in type I diabetes: evidence against its surface location on human islets P. G. COLMAN, I. L. CAMPBELL, T. W. H. KAY, AND L. C. HARRISON	1432
Thermic effect of glucose in obese subjects with non-insulin-dependent diabetes mellitus E. RAVUSSIN AND J. K. ZAWADZKI	1441
Insulinotropic effects of vanadate J. A. FAGIN, K. IKEJIRI, AND S. R. LEVIN	1448
Stable insulin preparation for implanted insulin pumps: laboratory and animal trials U. GRAU AND C. D. SAUDEK	1453
Regulation of vascular permeability in cell culture G. L. KING, A. B. BERMAN, S. BONNER-WEIR, AND M. P. CARSON	1460
Comparison of glomerular and mesangial prostaglandin synthesis and glomerular contraction in two rat models of diabetes mellitus R. BARNETT, L. SCHARSCHMIDT, Y.-H. KO, AND D. SCHLONDORFF	1468
Glyburide modulates insulin-mediated locomotor response of confluent cell cultures to wounding R. N. MASCARDO AND P. SHERLINE	1476

## ORGANIZATION SECTION

## Volume Indexes



When a type II diabetic patient needs more than diet, unique MICRONASE® Tablets (glyburide) are a logical first choice.

# Choosing antidiabetic

## 1. Micronase—a rational choice in type II diabetes


Insulin levels are normal or elevated in most patients with type II diabetes, although insulin action is markedly impaired. MICRONASE helps normalize the tissue response to endogenous insulin.

Initially, MICRONASE helps lower serum glucose in responsive patients by stimulating the release of additional insulin. As therapy continues, MICRONASE is believed to promote peripheral glucose metabolism by helping to correct defects at the cellular receptor and postreceptor levels.



## 2. Micronase—a single, daily dose provides 24-hour glycemic control

MICRONASE provides 24-hour control of blood glucose with a single, daily, low-milligram dose. MICRONASE may be taken with food, since food intake does not appear to affect its bioavailability.



## 3. Micronase—for the type II diabetic patient who is also hypertensive: Control without risk of water retention

This may also be significant for the type II diabetic patient with congestive heart failure. MICRONASE actually causes mild diuresis.



# therapy today

**4. Micronase—an important consideration in the type II diabetic patient with renal impairment: Control plus unique dual excretion... 50% urine, 50% bile**


Elimination of MICRONASE equally in bile and urine reduces the risk of drug accumulation, which may result in hypoglycemia. MICRONASE should be used with caution in patients with renal impairment; however, in a single-dose study, plasma clearance of MICRONASE was prolonged only in patients with severe renal impairment.

**5. Micronase—for the patient who fails on other diabetic therapy: Potency and dosage flexibility**

MICRONASE may prove effective when other drugs fail. Five mg of MICRONASE is approximately equivalent to 250 mg of chlorpropamide or 500 mg of acetohexamide in its ability to lower blood glucose. The dosage range of MICRONASE allows for greater dosage flexibility than other agents.

Overdosage of sulfonylureas, including MICRONASE, can cause hypoglycemia. Although the interpretations are controversial, the UGDP study reported in 1970 that the use of tolbutamide, an oral hypoglycemic drug, was associated with increased cardiovascular mortality.

**Upjohn** The Upjohn Company  
Kalamazoo, MI 49001



Your initial Rx in type II diabetes

**Micronase<sup>®</sup>**  
glyburide, **5 mg** Tablets

For brief summary of prescribing information, please turn page.

# Micronase® Tablets (glyburide)

**Dosage Guide:** \* Although relatively rare, hypoglycemia may occur during the conversion to MICRONASE from other therapy.

Prior therapy or condition	Considerations before starting therapy	Initial MICRONASE dose (mg/day)
Dietary therapy ineffective	No priming necessary	1.25 to 5 mg
Oral therapy	Discontinue oral hypoglycemic†	2.5 to 5 mg
Insulin therapy (<40 units/day)	Completely discontinue insulin injections under medical supervision	2.5 to 5 mg
Insulin therapy (>40 units/day)	Gradually discontinue insulin injections under close medical observation or hospitalization	5 mg

\*See complete prescribing information.

†See package insert for special precautions when transferring patients from chlorpropamide.

## Micronase Tablets (brand of glyburide tablets)

**CONTRAINDICATIONS:** MICRONASE Tablets are contraindicated in patients with: 1. Known hypersensitivity or allergy to the drug. 2. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin. 3. Type I diabetes mellitus, as sole therapy.

**SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY:** The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with noninsulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (Diabetes, 19 [Suppl 2]: 747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2-1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

**PRECAUTIONS: General - Hypoglycemia:** All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection and dosage and instructions are important to avoid hypoglycemic episodes. Renal or hepatic insufficiency may increase the risk of serious hypoglycemic reactions. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency, are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used. **Loss of Control of Blood Glucose:** In diabetic patients exposed to stress such as fever, trauma, infection or surgery, a loss of control may occur. It may then be necessary to discontinue MICRONASE and administer insulin. Adequate adjustment of dose and adherence to diet should be assessed before classifying a patient as a secondary failure. **Information for Patients:** Patients should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

**Laboratory Tests:** Response to MICRONASE Tablets should be monitored by frequent urine glucose tests and periodic blood glucose tests. Measurement of glycosylated hemoglobin levels may be helpful in some patients. **Drug Interactions:** The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. **Carcinogenesis, Mutagenesis, and Impairment of Fertility:** Studies in rats at doses up to 300 mg/kg/day for 18 months showed no carcinogenic effects. Glyburide is nonmutagenic when studied in the Salmonella microsome test (Ames test) and in the DNA damage/alkaline elution assay.

**Pregnancy: Teratogenic Effects:** Pregnancy Category B. Reproduction studies in rats and rabbits have revealed no evidence of impaired fertility or harm to the fetus due to glyburide. There are no adequate and well controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Insulin should be used during pregnancy to maintain blood glucose as close to normal as possible. **Nonteratogenic Effects:** Prolonged severe hypoglycemia (4 to 10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. MICRONASE should be discontinued at least two weeks before the expected delivery date.

**Nursing Mothers:** Some sulfonylurea drugs are known to be excreted in human milk. Insulin therapy should be considered. **Pediatric Use:** Safety and effectiveness in children have not been established.

**ADVERSE REACTIONS: Hypoglycemia:** See Precautions and Overdosage sections. **Gastrointestinal Reactions:** Cholestatic jaundice may occur rarely; MICRONASE Tablets should be discontinued if this occurs. Gastrointestinal disturbances, e.g., nausea, epigastric fullness, and heartburn, are the most common reactions, having occurred in 1.8% of treated patients during clinical trials. They tend to be dose-related and may disappear when dosage is reduced. Liver function abnormalities, including isolated transaminase elevations, have been reported. **Dermatologic Reactions:** Allergic skin reactions, e.g., pruritis, erythema, urticaria, and morbilliform or maculopapular eruptions, occurred in 1.5% of treated patients during clinical trials. These may be transient and may disappear despite continued use of MICRONASE; if skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas. **Hematologic Reactions:** Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas. **Metabolic Reactions:** Hepatic porphyria and disulfiram-like reactions have been reported with sulfonylureas; however, hepatic porphyria has not been reported with MICRONASE and disulfiram-like reactions have been reported very rarely.

**OVERDOSAGE:** Overdosage of sulfonylureas, including MICRONASE Tablets, can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate which will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours, since hypoglycemia may recur after apparent clinical recovery.

**Caution:** Federal law prohibits dispensing without prescription. Store at controlled room temperature 15°-30°C (59°-86°F). Dispensed in well closed containers with safety closures. Keep container tightly closed.

For additional product information see your Upjohn representative.

**Upjohn** THE UPJOHN COMPANY  
Kalamazoo, MI 49001, USA

B-3-S  
J-7349  
January 1987

## DECEMBER AUTHOR INDEX

(Volume 36, Number 12)

Andersson, A., 1401	Kraemer, N., 1379
Ashton, M.A., 1414	Lambourne, J.E., 1425
Barnett, R., 1468	Lang, F., 1356
Berman, A.B., 1460	Landström, A.S., 1401
Beyer, T.A., 1414	Levin, S.R., 1448
Bigley, N.J., 1408	Mascardo, R.N., 1476
Blay, R.A., 1408	Maugendre, D., 1356
Bonner-Weir, S., 1460	McNeill, G., 1386
Borg, H., 1401	Miller, M.A., 1365
Campbell, I.L., 1432	Neufeld, N.D., 1351
Carson, M.P., 1460	Petersson, B., 1401
Charbonnel, B., 1356	Polonsky, K.S., 1365
Colman, P.G., 1432	Rafford, C.E., 1414
Corbo, L.M., 1351	Ravussin, E., 1441
Curry, D.L., 1397	Reaven, E.P., 1397
DeFronzo, R.A., 1379	Reaven, G.M., 1397
Diaz, V.A., 1420	Rubenstein, A.H., 1365
Ellington, S.K.L., 1372	Sai, P., 1356
Fagin, J.A., 1448	Sandler, S., 1401
Frank, B.H., 1365	Saudek, C.D., 1453
Galloway, J.A., 1365	Scharschmidt, L., 1468
Goddu, K.J., 1414	Schlondorff, D., 1468
Grau, U., 1453	Shapiro, E.T., 1365
Groth, C.-G., 1401	Sherline, P., 1476
Harris, M., 1351	Sherwin, R.S., 1379
Harrison, L.C., 1432	Smith, R.A., 1408
Hellerström, C., 1401	Tillil, H., 1365
Houssaint, E., 1356	Tollemar, J., 1401
Hutson, N.J., 1414	Tomlinson, D.R., 1425
Ikejiri, K., 1448	Willars, G.B., 1425
Katz, M.A., 1386	Yeh, L.-A., 1414
Kay, T.W.H., 1432	Zawadzki, J.K., 1441
King, G.L., 1460	Zawalich, K.C., 1420
Ko, Y.-H., 1468	Zawalich, W.S., 1420
Koduri, A., 1351	



**Editor**

R. PAUL ROBERTSON, MD  
**Associate Editors**  
 ROBERT P. ELDE, PhD  
 FRANK Q. NUTTALL, MD, PhD  
 STEPHEN RICH, PhD  
 ROBERT L. SORENSON, PhD  
 MICHAEL W. STEFFES, MD, PhD

**Editorial Assistant**

LUCILLE MARIE SHRADER

**Editorial Board**

RICHARD BERGMAN, MD  
 WILLIAM S. BRIMIJOIN, PhD  
 H. FRANKLIN BUNN, MD  
 WILLIAM CHICK, MD  
 JOSEPH M. DAVIE, MD, PhD  
 WILLIAM DUCKWORTH, MD  
 DARYL GRANNER, MD  
 GEROLD M. GRODSKY, MD  
 JEFFREY B. HALTER, MD  
 EDWARD HORTON, MD  
 LEONARD JARETT, MD  
 TETSURO KONO, PhD  
 ÅKE LERNMARK, MD  
 S. MICHAEL MAUER, MD  
 STEWART A. METZ, MD  
 DANIEL H. MINTZ, MD  
 BARRY I. POSNER, MD  
 ROBERT SHERWIN, MD  
 DONALD F. STEINER, MD  
 MICHAEL P. STERN, MD  
 DAVID SUTHERLAND, MD  
 GORDON WEIR, MD  
 ROSALYN S. YALOW, PhD

**Publisher**

CAROLINE STEVENS  
**Director of Professional Publications**  
 BEVERLY BRITTAN COOK  
**Managing Editor**  
 ORIT LOWY

**Assistant Managing Editor**  
 DEMARIE JACKSON

**Assistant Editors**  
 PAMELA HARLEY-KARL  
 ANNE WILSON

**Publications Assistant**  
 YOLANDA CHRISTIE WALTERS

**American Diabetes Association  
 Officers 1987-88**

**Chairman of the Board**  
 S. DOUGLAS DODD

**President**  
 JOHN A. COLWELL, MD, PhD  
**Chairman of the Board-Elect**  
 WILLIAM A. MAMRACK

**President-Elect**  
 CHARLES CLARK, JR., MD

**Senior Vice-President**  
 LINDA S. HURWITZ, RN, MS  
**Vice-Chairman of the Board**  
 STERLING TUCKER

**Vice-Presidents**  
 SHERMAN M. HOLVEY, MD  
 ALAN D. CHERRINGTON, PhD

**Secretary**  
 GLORIA HIRSCH

**Treasurer**  
 GORDON R. MARDIS  
**Executive Vice-President**  
 ROBERT S. BOLAN

# diabetes

A JOURNAL OF THE AMERICAN DIABETES ASSOCIATION.

*Diabetes* and *Diabetes Care* are scientific research journals published by the American Diabetes Association. Both publish original high-quality reports on biomedical research related to the broad field of diabetes mellitus. *Diabetes* provides a forum for animal and human research primarily directed toward expanding knowledge of physiology and pathophysiology of diabetes mellitus. *Diabetes Care* provides a forum for applied research primarily directed toward improving the welfare of people with diabetes mellitus and enhancing understanding of the disease for health professionals.

The Journal does not publish material that has been reported elsewhere. In submitting an article the author(s) must state in the covering letter that the material has not been published elsewhere and has not been submitted for publication elsewhere. Prior publication specifically includes symposia, proceedings, preliminary communications, books, and invited articles. It is assumed that all human investigation shall have been conducted according to the principles expressed in the Declaration of Helsinki. Accepted manuscripts incur a charge of \$25 per printed page.

For studies involving experimental animals, state the species, strain, number used, and other pertinent descriptive characteristics. For human subjects or patients, describe their characteristics. When describing surgical procedures on animals, identify the preanesthetic and anesthetic agents used, and state the amount or concentration and the route and frequency of administration for each. The use of paralytic agents, such as curare or succinylcholine, is not an acceptable substitute for anesthetics. For other invasive procedures on animals, report the analgesic or tranquilizing drugs used; if none was used, provide justification for such exclusion. When reporting studies on unanesthetized animals or on humans, indicate that the procedures followed were in accordance with institutional guidelines.

In view of *The Copyright Revision Act of 1976*, all transmittal letters to the editor must contain the following language before manuscripts can be reviewed for possible publication: "In consideration of ADA's taking action in reviewing and editing my (our) submission, the author(s) undersigned hereby transfers, assigns, or otherwise conveys all copyright ownership to the ADA in the event that such work is published by the ADA." We regret that transmittal letters not containing the foregoing language signed by all authors of the manuscript will necessitate return of your manuscript.

Material appearing in *Diabetes* is copyrighted by the American Diabetes Association, Inc. Permission to reproduce all or parts of papers appearing in it may be granted under appropriate conditions and if proper credit is given. Such requests should

be addressed in writing to the Permissions Editor, accompanied by a letter of permission from the senior author.

All signed articles and editorials are the responsibility of the author(s) and not that of the American Diabetes Association. The Editors will be pleased to consider for publication papers presented at the Annual Meeting of the association.

**Rapid Publications:** Observations considered to be of unusual importance may be submitted as a Rapid Publication. Editorial decision will be made within 10 days after receipt of the manuscript. No written review or explanation of the decision will be provided. Rejected papers may be resubmitted as a regular manuscript and reviewed accordingly. Rapid Publications may not exceed 10 double-spaced typewritten pages (including figures, tables, and references). Accepted papers will be published in the earliest possible issue of the Journal.

Manuscripts should be typewritten, with double-spacing, and submitted in triplicate together with three copies of figures and photomicrographs. Manuscripts prepared in accord with the requirements specified in the document "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," *Annals of Internal Medicine* 96:766-71, 1982, will be considered for publication.

References should be presented in the style of the following examples and numbered in order of appearance in the text: For Periodicals—Banting FG, Best CH: The internal secretion of the pancreas. *J Lab Clin Med* 7:251-66, 1922. For Books—Allen M: *Studies Concerning Glycosuria and Diabetes*. Cambridge, MA, Harvard Univ. Press, 1913, p. 461.

A summary of the content of the paper of not more than 250 words should be provided. This should be self-contained and understandable without reference to the text.

Photographs, drawings, and figures should be suitable for reproduction. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The tops of photographs and figures should be indicated.

Galley proofs are sent to the principal author with a price list and order blank for reprints.

All manuscripts and related correspondence should be sent by 1st class mail addressed to R. Paul Robertson, M.D., University of Minnesota, P.O. Box 731, Minneapolis, MN 55440-0731. Express mail or correspondence requiring street address should be addressed to R. Paul Robertson, M.D., Phillips-Wangensteen Bldg., Rm. 6-124, 516 Delaware St. SE, Minneapolis, MN 55455. Editorial correspondence should be addressed to the Editorial Office, *Diabetes*, American Diabetes Association, Inc., National Service Center, 1660 Duke Street, Alexandria, Virginia 22314.


*Diabetes* (ISSN 0012-1797) is published monthly by the American Diabetes Association, Inc., 1660 Duke Street, Alexandria, Virginia 22314. Professional membership dues include \$70 designated for *Diabetes*. Subscription rates for nonmembers: \$70 for 1 year/\$125 for 2 years in the United States and Canada; \$105 for 1 year/\$195 for 2 years in all other countries. Foreign postage at \$12.50 per year applies to all foreign countries, including Canada, Mexico, and other countries in the Postal Union of the Americas and Spain. Individual copies: \$8 in the United States and Canada; \$12 in all other countries. Second-class postage paid at Alexandria, Virginia 22314, and at additional mailing offices. POSTMASTER: Send change of address to *Diabetes*, American Diabetes Association, P.O. Box 2055, Harlan, IA 51593-0238.

**Subscription correspondence** should be addressed to *Diabetes*, Subscription Department, P.O. Box 2055, Harlan, IA 51593-0238. Checks, money orders, and drafts for subscriptions should be made payable to the American Diabetes Association, Inc., and must accompany subscription orders. For more information call toll free 1-800-ADA-DISC 8:30 a.m. to 5:00 p.m., E.T., Monday through Friday. In Alaska, Hawaii, Virginia, and outside of the U.S., call 703-549-1500.

**Advertising inquiries** should be addressed to Peggy Donovan, Advertising Coordinator, American Diabetes Association, 1660 Duke St., Alexandria, VA 22314. Tel.: (703) 549-1500.



# *For diabetics with peripheral arterial disease...*



Circulatory insufficiency—a well-known factor in the pathogenesis of diabetic complications—predisposes diabetics to intermittent claudication.<sup>1</sup> In addition to narrowing of the blood vessels, two specific microcirculatory abnormalities—*decreased red cell flexibility and increased blood viscosity*—

are also associated with diabetes.<sup>1,2</sup> Although ideal glucose control might correct these abnormalities, glucose levels do fluctuate, and patients remain at risk.






# when microcirculatory blood flow improves, so does life.



Though glucose control may be imperfect, Trental® increases red cell flexibility and lowers blood viscosity. The flow of red cells—which are larger than the diameter of the microcirculatory vessels—is enhanced through the capillary bed, and tissue perfusion and oxygenation improve.<sup>3-5</sup>



Evidence of improved perfusion and oxygenation has been obtained from experimental measurements of partial pressures of oxygen ( $pO_2$ ) in the calf muscles of patients with limb ischemia given Trental®.<sup>6</sup>

## Significant improvement in stabilized diabetics<sup>2</sup>


The effectiveness of Trental® on intermittent claudication has been demonstrated in a controlled trial of 50 maturity-onset diabetics stabilized on insulin, oral antidiabetics, or diet alone. Eighty-four percent of patients receiving Trental® 400 mg b.i.d. showed a significant improvement in walking distance, compared with 17% of those on placebo.

Trental®-treated patients also had significant improvement in paresthesias, skin temperature, and subjective overall response.

Not a vasodilator • Not an anticoagulant  
Not related to aspirin or dipyridamole

# Trental®

(pentoxifylline) 400 mg  
Tablets



**The only proven-  
effective agent for  
intermittent claudication  
symptomatic of peripheral  
arterial disease**

Trental® can improve function and symptoms, but is not intended to replace more definitive therapy such as surgery.

Please see following page for references and brief summary of prescribing information.

© 1987 by Hoechst-Roussel Pharmaceuticals Incorporated.



**References:** 1. Oughton J, et al: Diabetes mellitus: Its effect on the flow properties of blood. *Horm Metab Res* 11 (Suppl): 112-129, 1981. 2. Schubotz R: Double-blind trial of pentoxifylline in diabetes with peripheral vascular disorders. *Pharmatherapeutica* 1(3): 172-179, 1976. 3. Dormandy JA, et al: Clinical, hemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. *Br Med J* 4: 576, 1973. 4. Reid HL, et al: Impaired red cell deformability in peripheral vascular disease. *Lancet* 1: 666, 1967. 5. Stormer B, et al: Rheological changes in the blood of patients with chronic arterial occlusive disease after the administration of vasoactive drugs. *Curr Med Res Opin* 4: 588, 1977. 6. Ehrly AM: Effects of orally administered pentoxifylline on muscular oxygen pressure in patients with intermittent claudication. *IRCS Med Sci* 10: 401, 1982.

#### Trental® (pentoxifylline) Tablets, 400 mg

A brief summary of the Prescribing Information follows.

#### INDICATIONS AND USAGE:

Trental® (pentoxifylline) is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Trental® (pentoxifylline) can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease.

#### CONTRAINDICATIONS:

Trental® (pentoxifylline) should not be used in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.

#### PRECAUTIONS:

**General:** Patients with chronic occlusive arterial disease of the limbs frequently show other manifestations of arteriosclerotic disease. Trental® (pentoxifylline) has been used safely for treatment of peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, but there have been occasional reports of angina, hypotension, and arrhythmia. Controlled trials do not show that Trental® (pentoxifylline) causes such adverse effects more often than placebo, but, as it is a methylxanthine derivative, it is possible some individuals will experience such responses.

**Drug Interactions:** Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Trental® (pentoxifylline) with and without anticoagulants or platelet aggregation inhibitors. Patients on warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examinations for bleeding including hematocrit and/or hemoglobin. Trental® (pentoxifylline) has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. Small decreases in blood pressure have been observed in some patients treated with Trental® (pentoxifylline); periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. If indicated, dosage of the antihypertensive agents should be reduced.

**Carcinogenesis, Mutagenesis and Impairment of Fertility:** Long-term studies of the carcinogenic potential of pentoxifylline were conducted in mice and rats by dietary administration of the drug at doses up to approximately 24 times (570 mg/kg) the maximum recommended human daily dose (MRHD) of 24 mg/kg for 18 months in mice and 18 months in rats with an additional 6 months without drug exposure in the latter. No carcinogenic potential for pentoxifylline was noted in the mouse study. In the rat study, there was a statistically significant increase in benign mammary fibroadenomas in females in the high dose group (24 X MRHD). The relevance of this finding to human use is uncertain since this was only a marginal statistically significant increase for a tumor that is common in aged rats. Pentoxifylline was devoid of mutagenic activity in various strains of *Salmonella* (Ames test) when tested in the presence and absence of metabolic activation.

**Pregnancy:** Category C. Teratogenic studies have been performed in rats and rabbits at oral doses up to about 25 and 10 times the maximum recommended human daily dose (MRHD) of 24 mg/kg, respectively. No evidence of fetal malformation was observed. Increased resorption was seen in rats at 25 times MRHD. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Trental® (pentoxifylline) should be used during pregnancy only if clearly needed.

**Nursing Mothers:** Pentoxifylline and its metabolites are excreted in human milk. Because of the potential for tumorigenicity shown for pentoxifylline in rats, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

**Pediatric Use:** Safety and effectiveness in children below the age of 18 years have not been established.

#### ADVERSE REACTIONS:

Clinical trials were conducted using either controlled-release Trental® (pentoxifylline) tablets for up to 60 weeks or immediate-release Trental® (pentoxifylline) capsules for up to 24 weeks. Dosage ranges in the tablet studies were 400 mg bid to tid and in the capsule studies, 200-400 mg tid.

The table summarizes the incidence (in percent) of adverse reactions considered drug related, as well as the numbers of patients who received controlled-

release Trental® (pentoxifylline) tablets, immediate-release Trental® (pentoxifylline) capsules, or the corresponding placebos. The incidence of adverse reactions was higher in the capsule studies (where dose related increases were seen in digestive and nervous system side effects) than in the tablet studies. Studies with the capsule include domestic experience, whereas studies with the controlled-release tablets were conducted outside the U.S. The table indicates that in the tablet studies few patients discontinued because of adverse effects.

#### INCIDENCE (%) OF SIDE EFFECTS

	Controlled-Release Tablets		Immediate-Release Capsules	
	Trental®	Placebo	Trental®	Placebo
(Numbers of Patients at Risk)	(321)	(128)	(177)	(138)
Discontinued for Side Effect	3.1	0	9.6	7.2
<b>CARDIOVASCULAR SYSTEM</b>				
Angina/Chest Pain	0.3	—	1.1	2.2
Arrhythmia/Palpitation	—	—	1.7	0.7
Flushing	—	—	2.3	0.7
<b>DIGESTIVE SYSTEM</b>				
Abdominal Discomfort	—	—	4.0	1.4
Belching/Flatus/Bloating	0.6	—	9.0	3.6
Diarrhea	—	—	3.4	2.9
Dyspepsia	2.8	4.7	9.6	2.9
Nausea	2.2	0.8	28.8	8.7
Vomiting	1.2	—	4.5	0.7
<b>NERVOUS SYSTEM</b>				
Agitation/Nervousness	—	—	1.7	0.7
Dizziness	1.9	3.1	11.9	4.3
Drowsiness	—	—	1.1	5.8
Headache	1.2	1.6	6.2	5.8
Insomnia	—	—	2.3	2.2
Tremor	0.3	0.8	—	—
Blurred Vision	—	—	2.3	1.4

Trental® (pentoxifylline) has been marketed in Europe and elsewhere since 1972. In addition to the above symptoms, the following have been reported spontaneously since marketing, or occurred in other clinical trials with an incidence of less than 1%; the causal relationship was uncertain: Cardiovascular—dyspnea, edema, hypotension; Digestive—anorexia, cholecystitis, constipation, dry mouth/thirst; Nervous—anxiety, confusion; Respiratory—epistaxis, flu-like symptoms, laryngitis, nasal congestion; Skin and Appendages—brittle fingernails, pruritus, rash, urticaria; Special Senses—blurred vision, conjunctivitis, earache, scotoma; and Miscellaneous—bad taste, excessive salivation, leukopenia, malaise, sore throat/swollen neck glands, weight change.

A few rare events have been reported spontaneously worldwide since marketing in 1972. Although they occurred under circumstances in which a causal relationship with pentoxifylline could not be established, they are listed to serve as information for physicians: Cardiovascular—angina, arrhythmia, tachycardia; Digestive—hepatitis, jaundice; and Hematologic and Lymphatic—decreased serum fibrinogen, pancytopenia, purpura, thrombocytopenia.

#### OVERDOSAGE:

Overdosage with Trental® (pentoxifylline) has been reported in children and adults. Symptoms appear to be dose related. A report from a poison control center on 44 patients taking overdoses of enteric-coated pentoxifylline tablets noted that symptoms usually occurred 4-5 hours after ingestion and lasted about 12 hours. The highest amount ingested was 80 mg/kg; flushing, hypotension, convulsions, somnolence, loss of consciousness, fever, and agitation occurred. All patients recovered.

In addition to symptomatic treatment and gastric lavage, special attention must be given to supporting respiration, maintaining systemic blood pressure, and controlling convulsions. Activated charcoal has been used to adsorb pentoxifylline in patients who have overdosed.

#### DOSAGE AND ADMINISTRATION:

The usual dosage of Trental® (pentoxifylline) in controlled-release tablet form is one tablet (400 mg) three times a day with meals.

While the effect of Trental® (pentoxifylline) may be seen within 2 to 4 weeks, it is recommended that treatment be continued for at least 8 weeks. Efficacy has been demonstrated in double-blind clinical studies of 6 months duration.

Digestive and central nervous system side effects are dose related. If patients develop these side effects it is recommended that the dosage be lowered to one tablet twice a day (800 mg/day). If side effects persist at this lower dosage, the administration of Trental® (pentoxifylline) should be discontinued.

Hoechst-Roussel Pharmaceuticals Inc.  
Somerville, New Jersey 08876

**Hoechst** 

## A giant step toward compliance...

- Medication
- Diet
- Stopping smoking
- Exercise

Ask your Hoechst-Roussel representative for information about this innovative patient education program.



# Trental®

400 mg Tablets  
(pentoxifylline)

**The only proven-effective agent for intermittent claudication symptomatic of peripheral arterial disease...**

The name and logo HOECHST are registered trademarks of Hoechst AG.

Q73130-287



*Unequalled injection comfort delivers  
unequalled patient compliance.*  
**B-D delivers.**

B-D MICRO-FINE® III is the thinnest, finest, sharpest needle ever made—for unequalled injection comfort.

The result is unequalled patient compliance with your insulin-administration instructions. No wonder physicians, nurses and hospitals use B-D syringes more than all other brands combined.



Your patients will find a money-back guarantee on every box of B-D syringes. It is our assurance to them of receiving the most comfortable injections they've ever had.






## Announcement

The American Diabetes Association is pleased to announce that David C. Robbins, MD, will become Editor of DIABETES CARE in January 1988. The Associate Editors will be Jorge Calles Escandon, MD, Kenneth C. Copeland, MD, John T. Devlin, MD, and Edward S. Horton, MD.

As of December 15, 1987, manuscripts submitted to DIABETES CARE should be sent to:

David C. Robbins, MD  
Editor, DIABETES CARE  
University of Vermont  
Department of Medicine  
Metabolic Unit, Given C-352  
Burlington, VT 05405



## Goals for Diabetes Education

**Goals for Diabetes Education** outlines the major objectives that must be covered to help your patients and their families gain the independence and control they need to effectively cope with diabetes.

Its useful checklist format leads you through the basic survival needs of individuals with diabetes to more advanced levels of continuing education, confidence-building, and life-style changes.

You'll review in-depth continuing education and counseling for type I and type II diabetes, as well as behavioral objectives for pregnant women with overt or gestational diabetes.

■ Definitions	■ Medication	■ Acute and
■ Nutrition	■ Monitoring	Long-Term
■ Exercise and Health Habits	■ Psychosocial Adjustment	Complications

### ORDER FORM

☐ **YES!** Please send me \_\_\_\_\_ copies of **Goals for Diabetes Education**.  
I have enclosed \$6.00 for **each** copy (includes shipping and handling).


Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_

State \_\_\_\_\_ Zip \_\_\_\_\_

**Make checks payable to the American Diabetes Association and mail to: American Diabetes Association, 1660 Duke St., Alexandria, VA 22314.**

**American Diabetes Association**



**LOWER HIS BLOOD PRESSURE**



**NOT HIS PERFORMANCE**

For a Brief Summary of Prescribing Information, please see the last page of this advertisement.



# START HIS DAY OUT RIGHT







FOR MANY HYPERTENSIVE PATIENTS  
**Start with Once-a-Day**

**VASOTEC<sup>®</sup>**

(ENALAPRIL MALEATE | MSD)

## Instead of a Beta Blocker

Certain CNS effects, such as impairment of memory, nightmares, or depression, have not been characteristic of VASOTEC.

### Little or No Interference with Physical or Mental Activity

Certain subjective symptoms such as malaise and drowsiness, which may interfere with physical or mental activity, have not been characteristic of VASOTEC—a fact that may be related to the specificity of action of VASOTEC on the renin-angiotensin-aldosterone system.

VASOTEC is contraindicated in patients who are hypersensitive to this product.

Angioedema of the face, extremities, lips, tongue, glottis, and/or larynx has been reported in patients treated with angiotensin-converting-enzyme (ACE) inhibitors, including VASOTEC (0.2% of patients treated with VASOTEC in clinical trials). In such cases, VASOTEC should be promptly discontinued and the patient carefully observed until the swelling disappears. Angioedema associated with laryngeal edema may be fatal. **Where there is involvement of the tongue, glottis, or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL), should be promptly administered.**

Excessive hypotension was rarely seen in uncomplicated hypertensive patients but is a possible consequence of enalapril use in severely salt/volume-depleted persons, such as those treated vigorously with diuretics or patients on dialysis. In using VASOTEC, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and the available data are insufficient to show that VASOTEC does not have a similar risk.

For a Brief Summary of Prescribing Information, please see the last page of this advertisement.



**It May Change  
the Way Your Patients Feel  
on Antihypertensive Therapy**





**Contraindications:** VASOTEC® (Enalapril Maleate, MSD) is contraindicated in patients who are hypersensitive to this product.

**Warnings:** *Angioedema:* Angioedema of the face, extremities, lips, tongue, glottis, and/or larynx has been reported in patients treated with ACE inhibitors, including VASOTEC. In such cases, VASOTEC should be promptly discontinued and the patient carefully observed until the swelling disappears. In instances where swelling has been confined to the face and lips, the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. **Where there is involvement of the tongue, glottis, or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL), should be promptly administered.** (See ADVERSE REACTIONS.)

*Hypotension:* Excessive hypotension was rarely seen in uncomplicated hypertensive patients but is a possible consequence of enalapril use in severely salt/volume-depleted persons such as those treated vigorously with diuretics or patients on dialysis. (See PRECAUTIONS, *Drug Interactions* and ADVERSE REACTIONS.) In patients with severe congestive heart failure, with or without associated renal insufficiency, excessive hypotension has been observed and may be associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death. Because of the potential fall in blood pressure in these patients, therapy should be started under very close medical supervision. Such patients should be followed closely for the first two weeks of treatment and whenever the dose of enalapril and/or diuretic is increased.

If hypotension occurs, the patient should be placed in supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses, which usually can be given without difficulty once the blood pressure has increased after volume expansion.

*Neutropenia/Agranulocytosis:* Another ACE inhibitor has been shown to cause agranulocytosis, and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment, especially if they also have a collagen vascular disease. Available data from clinical trials of enalapril are insufficient to show that enalapril does not cause agranulocytosis at similar rates. Foreign marketing experience has revealed several cases of neutropenia or agranulocytosis in which a causal relationship to enalapril cannot be excluded. Periodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered.

**Precautions:** *General: Impaired Renal Function:* As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe congestive heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors, including VASOTEC, may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death.

In clinical studies in hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine were observed in 20% of patients. These increases were almost always reversible upon discontinuation of enalapril and/or diuretic therapy. In such patients, renal function should be monitored during the first few weeks of therapy.

Some hypertensive patients with no apparent preexisting renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when VASOTEC has been given concomitantly with a diuretic. This is more likely to occur in patients with preexisting renal impairment. Dosage reduction of VASOTEC and/or discontinuation of the diuretic may be required.

**Evaluation of the hypertensive patient should always include assessment of renal function.** (See DOSAGE AND ADMINISTRATION in complete Prescribing Information.)

*Hyperkalemia:* Elevated serum potassium (greater than 5.7 mEq/L) was observed in approximately 1% of hypertensive patients in clinical trials. In most cases these were isolated values which resolved despite continued therapy. Hyperkalemia was a cause of discontinuation of therapy in 0.28% of hypertensive patients. Risk factors for the development of hyperkalemia may include renal insufficiency, diabetes mellitus, and the concomitant use of agents to treat hypokalemia. (See *Drug Interactions*.)

*Surgery/Anesthesia:* In patients undergoing major surgery or during anesthesia with agents that produce hypotension, enalapril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

**Information for Patients:**

*Angioedema:* Angioedema, including laryngeal edema, may occur especially following the first dose of enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.

*Hypotension:* Patients should be cautioned to report lightheadedness especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician.

All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

*Hyperkalemia:* Patients should be told not to use salt substitutes containing potassium without consulting their physician.

*Neutropenia:* Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia.

**NOTE:** As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

**Drug Interactions:**

*Hypotension: Patients on Diuretic Therapy:* Patients on diuretics and especially those in whom diuretic therapy was recently instituted may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril. The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril. If it is necessary to continue the diuretic, provide medical supervision for at least one hour after the initial dose. (See WARNINGS and DOSAGE AND ADMINISTRATION in complete Prescribing Information.)

*Agents Causing Renin Release:* The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release (e.g., diuretics).

*Other Cardiovascular Agents:* VASOTEC® (Enalapril Maleate, MSD) has been used concomitantly with beta-adrenergic-blocking agents, methylglucoside, nitrates, calcium-blocking agents, hydralazine, and prazosin without evidence of clinically significant adverse interactions.

*Agents Increasing Serum Potassium:* VASOTEC may attenuate potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated, they should be used with caution and with frequent monitoring of serum potassium.

*Pregnancy—Category C:* There was no fetotoxicity or teratogenicity in rats treated with up to 200 mg/kg/day of enalapril (333 times the maximum human dose). Fetotoxicity, expressed as a decrease in average fetal weight, occurred in rats given 1200 mg/kg/day of enalapril but did not occur when these animals were supplemented with saline. Enalapril was not teratogenic in rabbits. However, maternal and fetal toxicity occurred in some rabbits at doses of 1 mg/kg/day or more. Saline supplementation prevented the maternal and fetal toxicity seen at doses of 3 and 10 mg/kg/day, but not at 30 mg/kg/day (50 times the maximum human dose).

There are no adequate and well-controlled studies in pregnant women. VASOTEC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

*Nursing Mothers:* It is not known whether this drug is secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when VASOTEC is given to a nursing mother.

*Pediatric Use:* Safety and effectiveness in children have not been established.

**Adverse Reactions:** VASOTEC has been evaluated for safety in more than 10,000 patients, including over 1000 patients treated for one year or more. VASOTEC has been found to be generally well tolerated in controlled clinical trials involving 2677 patients.

The most frequent clinical adverse experiences in controlled trials were: headache (4.8%), dizziness (4.6%), and fatigue (2.8%). For the most part, adverse experiences were mild and transient in nature. Discontinuation of therapy was required in 6.0% of patients. In clinical trials, the overall frequency of adverse experiences was not related to total daily dosage within the range of 10 to 40 mg. The overall percentage of patients treated with VASOTEC reporting adverse experiences was comparable to placebo.

Other adverse experiences occurring in greater than 1% of patients treated with VASOTEC in controlled clinical trials were: diarrhea (1.6%), rash (1.5%), hypotension (1.4%), cough (1.3%), nausea (1.3%), and orthostatic effects (1.3%).

Clinical adverse experiences occurring in 0.5% to 1.0% of patients in the controlled trials or since the drug was marketed include:

*Cardiovascular:* Syncope, orthostatic hypotension, palpitations, chest pain.

*Nervous System:* Insomnia, nervousness, paresthesia, somnolence.

*Gastrointestinal System:* Abdominal pain, vomiting, dyspepsia.

*Renal:* Renal dysfunction, renal failure, oliguria. (See PRECAUTIONS and DOSAGE AND ADMINISTRATION in complete Prescribing Information.)

*Other:* Dyspnea, muscle cramps, hyperhidrosis, impotence, pruritus, asthenia.

*Angioedema:* Angioedema has been reported in patients receiving VASOTEC (0.2%). Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis, and/or larynx occurs, treatment with VASOTEC should be discontinued and appropriate therapy instituted immediately. (See WARNINGS.)

*Hypotension:* Combining the results of clinical trials in patients with hypertension or congestive heart failure, hypotension (including postural hypotension and other orthostatic effects) was reported in 2.3% of patients following the initial dose of enalapril or during extended therapy. In the hypertensive patients, hypotension occurred in 0.9% and syncope occurred in 0.5% of patients. Hypotension or syncope was a cause for discontinuation of therapy in 0.1% of hypertensive patients. (See WARNINGS.)

*Clinical Laboratory Test Findings:*

*Hyperkalemia:* (See PRECAUTIONS.)

*Creatinine, Blood Urea Nitrogen:* In controlled clinical trials, minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 0.2% of patients with essential hypertension treated with VASOTEC alone. Increases are more likely to occur in patients receiving concomitant diuretics or in patients with renal artery stenosis. (See PRECAUTIONS.)

*Hemoglobin and Hematocrit:* Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.3 g% and 1.0 vol%, respectively) occur frequently in hypertensive patients treated with VASOTEC but are rarely of clinical importance unless another cause of anemia coexists. In clinical trials, less than 0.1% of patients discontinued therapy due to anemia.

*Other (Causal Relationship Unknown):* Rarely, elevations of liver enzymes and/or serum bilirubin have occurred.

In marketing experience, rare cases of neutropenia, thrombocytopenia, and bone marrow depression have been reported.

**Dosage and Administration:** In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of VASOTEC. The diuretic should, if possible, be discontinued for two to three days before beginning therapy with VASOTEC to reduce the likelihood of hypotension. (See WARNINGS.) If the patient's blood pressure is not controlled with VASOTEC alone, diuretic therapy may be resumed.

If the diuretic cannot be discontinued, an initial dose of 2.5 mg (break the 5-mg tablet) should be used under medical supervision for at least one hour to determine whether excess hypotension will occur. (See WARNINGS and PRECAUTIONS, *Drug Interactions*.)

The recommended initial dose in patients not on diuretics is 5 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 10 to 40 mg per day administered in a single dose or in two divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. In such patients, an increase in dosage or twice-daily administration should be considered. If blood pressure is not controlled with VASOTEC alone, a diuretic may be added.

Concomitant administration of VASOTEC with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics may lead to increases of serum potassium (see PRECAUTIONS).

*Dosage Adjustment in Renal Impairment:* The usual dose of enalapril is recommended for patients with a creatinine clearance  $>30$  mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance  $\leq 30$  mL/min (serum creatinine  $\geq 3$  mg/dL), the first dose is 2.5 mg once daily. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily. For dialysis patients, the initial dose and the dose on dialysis days is 2.5 mg/day. Dosage on nondialysis days should be adjusted depending on blood pressure response.

For more detailed information, consult your MSD representative or see Prescribing Information. Merck Sharp & Dohme, Division of Merck & Co., Inc., West Point, PA 19486.

J7VS24(406R)


**MSD**  
**MERCK**  
**SHARP &**  
**DOHME**



# UNMISTAKABLY AHEAD OF THE REST

- Extremely accurate and reliable
- Most widely used system in hospitals<sup>1</sup>
- Portable and easy to use
- Most often recommended by diabetologists and endocrinologists<sup>1\*</sup>

**Accu-Chek<sup>®</sup> II**  
Blood Glucose Monitor



## THE LINE OF CONFIDENCE<sup>SM</sup> IN DIABETES CONTROL

For more information, please call toll-free 1-800-858-8072. Available at most retail pharmacies.

\*From a group of physicians surveyed. Reference: 1. Data on file, Boehringer Mannheim Diagnostics. © 1987 Boehringer Mannheim Corporation. All rights reserved.







# "MY DAILY INSULIN INTAKE IS NO LONGER GUESSWORK."

"I am feeling almost 100% now. I am back with my family and able to do some of the things we really love.

Without my GLUCOSCAN Blood Glucose Meter, my daily insulin intake would be just guesswork. My family has been so supportive—my husband saw an advertisement for the GLUCOSCAN Meter. He said, 'We're getting this for you right now.' And, we have never been sorry we bought it.

"Now, my children even help me do my blood glucose test. The GLUCOSCAN is that easy. It's almost as if it has become another member of the family."

GLUCOSCAN is the blood glucose meter that keeps people with diabetes on the go and in tune with themselves and the rest of the world. It's so easy to use, blood glucose monitoring becomes second nature.

Factory calibrated to help ensure accuracy, you can trust your GLUCOSCAN Meter to take care of your blood glucose test results so you can concentrate on the rest of your life.

GLUCOSCAN Blood Glucose Meters are backed by LifeScan's reputation for prompt and caring service. And, LifeScan offers a money-back guarantee with each and every GLUCOSCAN Meter. The GLUCOSCAN Meter is available from over 3,000 authorized distributors nationwide. For the distributor near you, or for more information, call TOLL-FREE:

United States	1 800 227-8862
Canada	1 800 663-5521



**GLUCOSCAN™: A friend for life.**

*Frances Roberts, age 42,  
has used GLUCOSCAN  
Blood Glucose Meter for  
1 year.*


**LIFESCAN** INC.

a Johnson & Johnson company  
Mountain View, California 94043

# Essential diabetes work.



# Essential diabetes reading.



## DIABETES—An Essential Research Tool

The leading U.S. Journal on basic diabetes research, presenting the latest laboratory findings from the world's most eminent scientists. Published monthly, plus supplements, DIABETES features major scientific papers and review articles, editorials, and ADA news.

Upcoming issues of DIABETES will feature the latest findings on such important topics as early detection of vascular dysfunction in NIDDM, effects on insulin, HLA-DR antigens as markers for B-cell destruction in NIDDM patients, and more. Plus, you'll have immediate access to major research studies by Roger Unger... Paul Lacy... Bernard Jeanrenaud... George Eisenbarth... Jørn Nerup... David Sutherland... and scores of other authorities in the field of diabetes research.

## DIABETES CARE—Research With Clinical Application

Now published 10 times a year (plus supplements), DIABETES CARE is the world's most widely read journal that keeps up with today's rapid changes in diabetes clinical research and treatment. DIABETES CARE offers practitioners, dietitians, educators, and researchers the latest clinical findings that relate to diagnosis, diet, exercise, monitoring, drug therapy, and complications and their management.

DIABETES CARE offers valuable insights on such critical areas of concern as the reduction in cardiovascular risk factors with intensive diabetes treatment in NIDDM, effect of temperament on metabolic control in children with diabetes mellitus, alcohol abuse and diabetic ketocidosis, relationship of body fat distribution patterns to atherogenic risk factors in NIDDM, and much more.

## SUBSCRIPTION ORDER FORM

	<b>DIABETES</b>	<b>DIABETES CARE</b>
Please start my subscription for:	<input type="checkbox"/> US/CANADA	<input type="checkbox"/> US/CANADA
	12 issues—\$70.00	10 issues—\$55.00
		<b>International</b>
	<input type="checkbox"/> \$105.00	<input type="checkbox"/> \$82.00

Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Zip/Province/City/Country (International only) \_\_\_\_\_

Please send payment with your order to:  
American Diabetes Association  
Subscription Services Dept.  
P.O. Box 2055  
Harlan, IA 51593-0293, USA.

 **American Diabetes Association, Inc.**





First hundreds...

Then thousands...

Soon more than a million.

Soon more than a million insulin users will be taking Humulin.


And no wonder. Humulin is identical to the insulin produced by the human pancreas—except that it is made by rDNA technology.

Humulin is not derived from animal pancreases. So it contains none of the animal-source pancreatic impurities that may contribute to insulin allergies or immunogenicity.

The clinical significance of insulin antibodies in the complications of diabetes is uncertain at this time. However, high antibody titers have been shown to decrease the small amounts of endogenous insulin secretion some insulin users still have. The lower immunogenicity of Humulin has been shown to result in lower insulin antibody titers; thus, Humulin may help to prolong endogenous insulin production in some patients.

**Any change of insulin should be made cautiously and only under medical supervision.** Changes in refinement, purity, strength, brand (manufacturer), type (regular, NPH, Lente®, etc), species/source (beef, pork, beef-pork, or human), and/or method of manufacture (recombinant DNA versus animal-source insulin) may result in the need for a change in dosage.

DIET...EXERCISE...

**Humulin®**   
human insulin  
(recombinant DNA origin)


For your insulin-using patients

© 1987, ELI LILLY AND COMPANY

HI-2901-T



**Lilly Leadership**  
IN DIABETES CARE



Eli Lilly and Company  
Indianapolis, Indiana  
46285




# TIMING IS KEY





# EVERYTHING



## Effective control time and time again<sup>1</sup>

Effective control of fasting and postprandial glucose—patient after patient, meal after meal, year after year.

## Insulin when it's needed

Insulin levels are rapidly elevated in response to a meal, then return promptly to basal levels after the meal challenge subsides.

## Timed to minimize risks

Rapidly metabolized and excreted, with an excellent safety profile.<sup>1</sup> As with all sulfonylureas, hypoglycemia may occur.

In concert with diet in non-insulin-dependent diabetes mellitus

**Glucotrol<sup>®</sup>**  
(glipizide) 5-mg and 10-mg  
Scored Tablets



**SYNCHRONIZED  
SULFONYLUREA THERAPY**



*Please see brief summary of Glucotrol<sup>®</sup> (glipizide) prescribing information on next page.*

**ROERIG**   
A division of Pfizer Pharmaceuticals  
New York, New York 10017



# Reference:

1. Sachs R, Frank M, Fishman SK: Overview of clinical experience with glipizide. In *Glipizide: A Worldwide Review*. Princeton, NJ, Excerpta Medica, 1984, pp 163-172.

## GLUCOTROL® (glipizide) Tablets

### Brief Summary of Prescribing Information

**INDICATIONS:** GLUCOTROL is indicated as an adjunct to diet for the control of hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM, type II) after an adequate trial of dietary therapy has proved unsatisfactory.

**CONTRAINDICATIONS:** GLUCOTROL is contraindicated in patients with known hypersensitivity to the drug or with diabetic ketoacidosis, with or without coma, which should be treated with insulin.

**SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY:** The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes*, 19, supp. 2:747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2-1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of GLUCOTROL and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

**PRECAUTIONS: Renal and Hepatic Disease:** The metabolism and excretion of GLUCOTROL may be slowed in patients with impaired renal and/or hepatic function. Hypoglycemia may be prolonged in such patients should it occur.

**Hypoglycemia:** All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemia. Renal or hepatic insufficiency may increase the risk of hypoglycemic reactions. Elderly, debilitated or malnourished patients and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly or people taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

**Loss of Control of Blood Glucose:** A loss of control may occur in diabetic patients exposed to stress such as fever, trauma, infection or surgery. It may then be necessary to discontinue GLUCOTROL and administer insulin.

**Laboratory Tests:** Blood and urine glucose should be monitored periodically. Measurement of glycosylated hemoglobin may be useful.

**Information for Patients:** Patients should be informed of the potential risks and advantages of GLUCOTROL, of alternative modes of therapy, as well as the importance of adhering to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

**Drug Interactions:** The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including non-steroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. *In vitro* studies indicate that GLUCOTROL binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to a clinical situation. Certain drugs tend to produce hyperglycemia and may lead to loss of control, including the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, or vaginal preparations of miconazole is not known.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** A 20-month study in rats and an 18-month study in mice at doses up to 75 times the maximum human dose revealed no evidence of drug-related carcinogenicity. Bacterial and *in vivo* mutagenicity tests were uniformly negative. Studies in rats of both sexes at doses up to 75 times the human dose showed no effects on fertility.

**Pregnancy:** Pregnancy Category C. GLUCOTROL (glipizide) was found to be mildly fetotoxic in rat reproductive studies at all dose levels (5-50 mg/kg). This fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide and tolazamide. The effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of GLUCOTROL. In studies in rats and rabbits no teratogenic effects were found. There are no adequate and well controlled studies in pregnant women. GLUCOTROL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

**Nonteratogenic Effects:** Prolonged severe hypoglycemia has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. GLUCOTROL should be discontinued at least one month before the expected delivery date.

**Nursing Mothers:** Since some sulfonylurea drugs are known to be excreted in human milk, insulin therapy should be considered if nursing is to be continued.

**Pediatric Use:** Safety and effectiveness in children have not been established.

**ADVERSE REACTIONS:** In controlled studies, the frequency of serious adverse reactions reported was very low. Of 702 patients, 11.8% reported adverse reactions and in only 1.5% was GLUCOTROL discontinued.

**Hypoglycemia:** See PRECAUTIONS and OVERDOSAGE sections.

**Gastrointestinal:** Gastrointestinal disturbances, the most common, were reported with the following approximate incidence: nausea and diarrhea, one in 70; constipation and gastralgia, one in 100. They appear to be dose-related and may disappear on division or reduction of dosage. Cholestatic jaundice may occur rarely with sulfonylureas. GLUCOTROL should be discontinued if this occurs.

**Dermatologic:** Allergic skin reactions including erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been reported in about one in 70 patients. These may be transient and may disappear despite continued use of GLUCOTROL; if skin reactions persist, the drug should be discontinued. Porphyrria cutanea tarda and photosensitization reactions have been reported with sulfonylureas.

**Hematologic:** Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.

**Metabolic:** Hepatic porphyrria and disulfiram-like alcohol reactions have been reported with sulfonylureas. Clinical experience to date has shown that GLUCOTROL has an extremely low incidence of disulfiram-like reactions.

**Endocrine Reactions:** Cases of hyponatremia and the syndrome of inappropriate antidiuretic hormone (SIADH) secretion have been reported with this and other sulfonylureas.

**Miscellaneous:** Dizziness, drowsiness, and headache have been reported in about one in fifty patients treated with GLUCOTROL. They are usually transient and seldom require discontinuance of therapy.

**OVERDOSAGE:** Overdosage of sulfonylureas including GLUCOTROL can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours since hypoglycemia may recur after apparent clinical recovery. Clearance of GLUCOTROL from plasma would be prolonged in persons with liver disease. Because of the extensive protein binding of GLUCOTROL (glipizide), dialysis is unlikely to be of benefit.

**DOSEAGE AND ADMINISTRATION:** There is no fixed dosage regimen for the management of diabetes mellitus with GLUCOTROL. In general, it should be given approximately 30 minutes before a meal to achieve the greatest reduction in postprandial hyperglycemia.

**Initial Dose:** The recommended starting dose is 5 mg before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg. Dosage adjustments should ordinarily be in increments of 2.5-5 mg, as determined by blood glucose response. At least several days should elapse between titration steps.

**Maximum Dose:** The maximum recommended total daily dose is 40 mg.

**Maintenance:** Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided.

**HOW SUPPLIED:** GLUCOTROL is available as white, dye-free, scored diamond-shaped tablets imprinted as follows: 5 mg tablet—Pfizer 411 (NDC 5 mg 0049-4110-66) Bottles of 100, 10 mg tablet—Pfizer 412 (NDC 10 mg 0049-4120-65) Bottles of 100.

**CAUTION:** Federal law prohibits dispensing without prescription.

More detailed professional information available on request.

## STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION (Required by 39 U.S.C. 3685)

**1A.** Title of Publication: Diabetes, UPS 156-240. **1B.** Publication No. 00121797. **2.** Date of filing: October 13, 1987. **3.** Frequency of Issue: Monthly. **3A.** No. of issues published annually: 12. **3B.** Annual subscription price: \$70.00. **4.** Complete mailing address of known office of publication: American Diabetes Association, Inc., 1660 Duke St., Alexandria, VA 22314. **5.** Complete mailing address of the headquarters of general business offices of the publisher: American Diabetes Association, Inc., 1660 Duke St., Alexandria, VA 22314. **6.** Full names and complete mailing address of publisher, editor, and managing editor. Publisher: Caroline Stevens, American Diabetes Assn., Inc., 1660 Duke St., Alexandria, VA 22314. Editor: R. Paul Robertson, MD, American Diabetes Assn., Inc., 1660 Duke St., Alexandria, VA 22314. Managing Editor: Orit Lowy, American Diabetes Assn., Inc., 1660 Duke St., Alexandria, VA 22314. **7.** Owner: (A Nonprofit Voluntary Health Agency) American Diabetes Association, Inc., 1660 Duke St., Alexandria, VA 22314. **8.** Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages or other securities: None. **9.** The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes has not changed during the preceding 12 months. **10.** Extent and nature of circulation: **A.** Average no. copies each issue during preceding 12 months, 11,000; Actual no. copies of single issue published nearest to filing date, 12,000. **B.** Paid and/or requested circulation: Sales through dealers and carriers, street vendors and counter sales, none. Mail subscription: Average no. copies each issue during preceding 12 months, 9,208; Actual no. copies of single issue published nearest to filing date, 9,738. **C.** Total paid and/or requested circulation: Average no. copies each issue during preceding 12 months, 9,208; Actual no. copies of single issue published nearest to filing date, 9,738. **D.** Free distribution by mail, carrier, or other means; samples, complimentary, and other free copies: Average no. copies each issue during preceding 12 months, 304; Actual no. copies of single issue published nearest to filing date, 337. **E.** Total distribution: Average no. copies each issue during preceding 12 months, 9,512; Actual no. copies of single issue published nearest to filing date, 10,075. **F.** Copies not distributed: 1. Office use, left over, unaccounted, spoiled after printing: Average no. copies each issue during preceding 12 months, 1,488; Actual no. copies of single issue published nearest to filing date, 1,925. **2.** Return from News Agents: none. **G.** Total: Average no. copies each issue during preceding 12 months, 11,000; Actual no. copies of single issue published nearest to filing date, 12,000.

**11.** I certify that the statements made by me above are correct and complete: Caroline A. Stevens, Publisher.



AMERICAN DIABETES ASSOCIATION

## MISSING ISSUE POLICY

Replacements for missing issues will be sent free of charge provided we are notified within two months of the issue date for U.S. and Canadian subscribers/members or within four months of the issue date for all other foreign subscribers/members.

To order back issues, please prepay in U.S. funds drawn on a U.S. bank.

Diabetes and Diabetes Care  
(Single copy price)

U.S.	Foreign Surface Mail	Foreign Air Mail
\$8.00	\$10.50	\$14.00

Make check payable to:

American Diabetes Association  
Back Issue Department  
1660 Duke Street  
Alexandria, VA 22314

ROERIG



A division of Pfizer Pharmaceuticals  
New York, New York 10017



NO TIMING, WIPING OR BLOTTING.

**Finally,  
reliable blood glucose  
monitoring  
takes just  
one touch.**





I N T R O D U C I N G

# ONE TOUCH<sup>TM</sup> SYSTEM

## A revolutionary blood glucose monitoring system from LifeScan.

**One Touch—  
the first truly  
simple system.**

The new One Touch System makes reliable blood glucose monitoring easier than ever. With One Touch, results can be achieved by touching the reagent pad just once—to apply blood—because no wiping or blotting is required.


**One Touch—no timing,  
no wiping, no blotting,  
no user demands.**

The One Touch System eliminates three major demands on your patients: starting the test, timing the test and removing the blood. With the test strip in the meter, the patient presses Power, then applies the blood sample to the reagent pad at any time. At this


**1. Insert test strip.**



**2. Press POWER.**







point the meter takes over, starting the test automatically when it detects blood on the reagent pad. No blood removal is required, and results appear in just 45 seconds. *The opportunity for procedural error is virtually eliminated.*

**One Touch—easier to use, easier to handle.**

The One Touch Meter provides a stable platform for the test strip while the blood sample

is applied. The reagent pad is smaller, so less blood is required for each test. The test strip is wider, so it's easier to handle.

**One Touch—added features for greater convenience and confidence.**

One Touch is the first blood glucose meter to provide interactive messages in plain English on a large, easy-to-read display.

With each One Touch test, numerous system self-checks (optics, software, memory function, strip presence and battery) are performed. And 250 previous test results may be recalled from memory.

**One Touch—designed for technique-independent testing.**

When blood glucose monitoring is kept simple, results are more reliable. The One Touch testing procedure accomplishes this goal.

**3. Apply sample.**

**Result appears in just 45 seconds—with no timing, wiping, or blotting.**



**ONE TOUCH™**  
SYSTEM





**The Complete One Touch™ System Includes:**  
 One Touch Meter with Carry Case  
 One Touch Test Strips  
 Penlet™ Automatic Sampling Pen and Lancets  
 Glucose Control Solution  
 Instructional Audio Cassette  
 Owner's Booklet  
 Logbook

# Technology that tests the glucose, not the patient.

## Specifications:

### Fast test time

Results appear in just 45 seconds.

### Wider dynamic range

0 to 600 mg/dL (0 to 33.3 mmol/L).

### Unsurpassed accuracy

When compared to a clinical laboratory instrument (YSI Model 23A Glucose Analyzer) at three different clinical locations, results from patients using the One Touch System demonstrated excellent correlation with the reference method.

slope 1.02

y intercept 4.7 mg/dL

correlation coefficient (r) 0.979


### Automatic memory

Stores most recent 250 readings. Data port for transferring memory contents to Data Manager™ unit for printed test histories with time and date.

### Easy-to-read display

Alphanumeric; dot matrix LCD.

## Comparison of One Touch used by patients vs. laboratory reference method\*



## Customer satisfaction guarantee

No risk money-back guarantee on One Touch System within 30 days of purchase. Full three-year warranty on One Touch Meter.

**For a One Touch demonstration,** contact your LifeScan Professional Representative. For the name of your local Representative, call toll-free:  
**In the U.S.: 1 800 227-8862**  
**In Canada: 1 800 663-5521**

\*Data on file, LifeScan, Inc.

# ONE TOUCH™

SYSTEM

**LIFESCAN** INC.

a Johnson & Johnson company  
 Mountain View, California 94043